TrialSIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Trial details
- Registry ID
- NCT05303519
- Phase
- Phase 3
Drug research
safusidenib
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as AB-218; DS-1001b
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519 | NUVB | Phase 3 | Recruiting | 2028-12-01Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |